Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teverelix DP in men following a first episode of acute urinary retention (AUR)
NCT07733934Phase 2Not yet recruiting
- Sponsor
- Antev
- Start
- Sep 2026
- Primary completion
- May 2028
01
Overview
A Phase 2 trial of teverelix in acute urinary retention, benign prostatic hyperplasia (BPH), sponsored by Antev. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
teverelix
03
Conditions
acute urinary retentionbenign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07733934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07733934.